| Bioactivity | KIRA9 is a potent IRE1 inhibitor (IC50=4.8 μM in INS-1 cells). KIRA9 is able to fully engage the ATP-binding site of IRE1α. KIRA9 can block ER-localized mRNA decay and apoptosis[1]. |
| Invitro | KIRA9 (0-30 μM; 2 hours) blocks the autophosphorylation induced by conditional overexpression of IRE1α in INS-1 cells (IC50=4.8 μM)[1].KIRA9 (20 μM; 2 hours) reduces the mRNA expression of Bloc1s1, Ins1 and Ins2 in INS-1 cells[1].KIRA9 (20 μM; 2 hours) blunts IRE1α-dependent decay (RIDD) in ER-stressed INS-1 cells[1].KIRA9 (20 μM; 1 hour) markedly reduces the generation of cleaved caspase-3 and shows significant cytoprotective efficacy[1].KIRA9 (0-20 μM; 3 days) reduces XBP1s expression, plasma cell differentiation and IgM secretion in a dose-dependent manner[1]. Apoptosis Analysis Cell Line: |
| Name | KIRA9 |
| Formula | C27H27F3N6O3S |
| Molar Mass | 572.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |